TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05566951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial program
Description: A technology-based model-based psychosocial empowerment program will be implemented for parents and children in the control group.

Intervention type: OTHER
Group type: OTHER
Intervention: Standart care
Description: Parents and children in the intervention group will be applied standard support approaches to be applied in the center where they receive treatment.
Study: NCT04828343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozanolixizumab
Description: Study participants will receive a single dose rozanolixizumab subcutaneously administered by manual push or a syringe driver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study participants will receive a single dose placebo subcutaneously administered by manual push or a syringe driver.
Study: NCT04856813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy active
Description: massage or ischemic compression with active contraction, tha will be isometric or concentric.
Study: NCT06206174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-814
Description: Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
Study: NCT04856813

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: massage or isquemic compression without contraction
Study: NCT06517199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine 2.5 MG
Description: olanzapine 2.5 mg/day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine 5 MG
Description: olanzapine 5 mg/day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 1 tab/day for 28 days
Study: NCT04908618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital impression for normal abutment
Description: Accuracy of scan body impression
Study: NCT04739514

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises for dysphagia rehabilitation
Description: Diet modifications, postural exercises, compensatory exercises, swallowing exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises for dysphagia rehabilitation
Description: Diet modifications, postural exercises, compensatory exercises, swallowing exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises for dysphagia rehabilitation
Description: Diet modifications, postural exercises, compensatory exercises, swallowing exercises
Study: NCT05914168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breast Tomosynthesis
Description: Three dimensional mammography
Study: NCT05747456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPN-21-SENSE
Description: Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.

Intervention type: DEVICE
Group type: OTHER
Intervention: IPN-21-SENSE
Description: Up to 2.0 mL will be injected in the zygomaticomalar region and optionally up to 2.0 mL in the anteromedial cheek at the first session, on each side of the face.~Up to 1.0 mL in the zygomaticomalar region and optionally up to 1.0 mL in the anteromedial cheek for the optional touch-up session, on each side of the face.
Study: NCT06205888

Intervention type: OTHER
Intervention: 18F-LNC1007（18F-FAPI-RGD） PET/CT和18F-FDG PET/CT
Description: Eligible subjects will receive 18F-LNC1007 (18F-FAPI-RGD) PET/CT and 18F-FDG PET/CT examinations within 1 week (the interval between the two examinations shall not exceed 7 days, and the scanning parameters, scanning range, image reconstruction methods, etc., shall be consistent). That is, with 18F-LNC1007 (18F-FAPI-RGD) PET/CT time as D0, 18F-FDG PET/CT examination can accept data from D1 to D7
Study: NCT06539013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: remifentanil infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N2O
Description: Use of N2O for analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Use of Fentanylfor analgesia
Study: NCT04795232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COD45
Description: Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 27.6 meters and will include two changes of direction of 45 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COD90
Description: Participants will perform 2 sets of 10 sprints. The total distance for each sprint will be 21.2 meters and will include two changes of direction of 90 degrees. The recovery time will be 16 seconds between sprints and 2.20 minutes between sets
Study: NCT05386355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine Uptake App
Description: A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Health App
Description: A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.
Study: NCT05208151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Creative Drama Education
Description: Effective Communication with Creative Drama in Health Course will be given to students for 2 hours a week for 14 weeks.
Study: NCT05632887

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06011148

Intervention type: DEVICE
Intervention: Perceval S sutureless heart valve
Description: Aortic Valve Replacement with Perceval S sutureless heart valve
Study: NCT05030012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Control
Description: The purpose of this intervention is to evaluate that the efficacy and safety during the automated performance of the Vapotherm OAM are not inferior to standard care practice (manual control) in maintaining SpO2 levels of 90-95% in preterm infants requiring oxygen adjustments while being treated with high velocity nasal insufflation (HVNI) therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Control
Description: The purpose of this intervention is to establish an active comparator via standard care practice against which to evaluate the efficacy and safety of the automated arm of the study, for determination of non-inferiority of that automated control arm to manual control in maintaining SpO2 levels of 90-95% in preterm infants being treated with high velocity nasal insufflation (HVNI) therapy.
Study: NCT05365503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shamiri Intervention
Description: The first two sessions focus on the concept of growth mindset, the third session focuses on gratitude, and the fourth and final session focuses on values. In session one, participants are guided through a Growth mindset intervention designed to convey the idea that people and their situations can change for the better. In session two, group leaders introduce a discussion and activities about effective strategies for growth. Then, the group leaders introduce a framework for problem solving. In session three, group leaders emphasize the importance of verbalizing and consciously thinking about Gratitude, as well as its benefits for well-being. In the final session, participants are introduced to the concept of values. Participants discuss stories of culturally pertinent role models, with an emphasis on the values these individuals display, and how their values guided their life decisions and led to success and happiness.
Study: NCT04797559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SZMN Block
Description: Suprazygomatic Maxillary Nerve (SZMN) Blocks bilaterally near the temples of the patient
Study: NCT06517004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWCAR201
Description: Autologous CD19/CD20-directed CAR-T cells, single infusion intravenously
Study: NCT05687669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
Description: Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
Description: Glyceryl trinitrate vs phentolamine for prophylaxis against renal impairment
Study: NCT05094388

Intervention type: OTHER
Intervention: Admitted to intensive care units
Description: Admitted to intensive care units
Study: NCT05932212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: 15mg/kg, Q3W, IV infusion,
Study: NCT05150899

Intervention type: DRUG
Intervention: Tamsulosin Hcl 0.4Mg Cap
Description: alpha blocker
Study: NCT06320561

Intervention type: OTHER
Intervention: Longitudinal prospective cohort study
Description: Patients after stroke who meet the in- and exclusion criteria will be examined 4 times during the first 3 months after their stroke.
Study: NCT05150899

Intervention type: DRUG
Intervention: Tamsulosin Hcl 0.4Mg Cap
Description: alpha blocker

Intervention type: DRUG
Intervention: fexofenadine 180 mg Oral tablet
Description: antihistaminic
Study: NCT05938699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NCX 470
Description: NCX 470 0.1% vs Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NCX 0.1% vs Placebo
Study: NCT04697680

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm 1
Description: A sleep extension algorithm (algorithm 1) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm 2
Description: A sleep extension algorithm (algorithm 2) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm 3
Description: A sleep extension algorithm (algorithm 3) will be calculated and implemented based on information obtained from Sleep Diary and Fitbit data.
Study: NCT04800172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: administration of roflumilast 500 mcg tablet once daily for 3 months.
Study: NCT06220539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casting and supervised rehabilitation
Description: casting (8 weeks) followed by supervised rehabilitation
Study: NCT04800172

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of placebo tablet once daily for 3 months.
Study: NCT05633017

Intervention type: COMBINATION_PRODUCT
Intervention: CereVu Objective Dyspnea Score
Description: Small forehead wearable and mobile app

Intervention type: COMBINATION_PRODUCT
Intervention: CereVu Objective Dyspnea Score
Description: Small forehead wearable and mobile app
Study: NCT06083064

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal imaging
Description: Abdominal ultrasound and/or abdominal CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Score based selective abdominal imaging
Description: Abdominal imaging is done selectively based on Adult Appendicitis Score

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Score based selective observation combined with selective abdominal imaging
Description: Observation based on Appendicitis Severity Score combined Adult Appendicitis Score based selective abdominal imaging
Study: NCT05756075

Intervention type: BEHAVIORAL
Intervention: Aerobic exercise training
Description: Participants will follow a personalized aerobic exercise training program twice a week at the physiotherapist. The intensity of the program is based on the results of the 6MWT according to the most recent guidelines for physiotherapy for PD and COPD

Intervention type: BEHAVIORAL
Intervention: Aerobic exercise training
Description: Participants will follow a personalized aerobic exercise training program twice a week at the physiotherapist. The intensity of the program is based on the results of the 6MWT according to the most recent guidelines for physiotherapy for PD and COPD
Study: NCT04923659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: 600 mg reconstituted as one table. Administered once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: 2.5 mg mg reconstituted as one table. Administered once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 150 mgmg reconstituted as one table. Administered once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: 30 mg reconstituted as one table. Administered once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered once
Study: NCT06073145

Intervention type: DEVICE
Intervention: conventional transcranial Doppler probe and wearable ultrasound patch.
Description: Comparison of the measurements from conventional transcranial Doppler probe and wearable ultrasound patch.
Study: NCT05584319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 Mg
Description: subjects in Empagliflozin group takes Empagliflozin 10mg per day
Study: NCT05273671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: will receive with a saline solution 10 min before the end of surgery
Study: NCT05246358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChoniSense Polso
Description: A range of stable respiratory rates was elicited from each volunteer test subject. The rates were 5, 10, 15, 20, 25, 30, 35, 40 and 45 breaths per minute; with some natural variation from these exact numbers.~Each subject was instrumented with an open system mask that allows for measurement of the end tidal carbon dioxide (EtCO2) respiratory rate and tidal volume. The EtCO2 monitor was used as the Accuracy Reference Device (Reference) in this study.
Study: NCT06385626

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raspberry leaf tea
Description: 10 g of raspberry leaf tea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry leaf tea
Description: 10 g of raspberry leaf tea

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raspberry leaf tea
Description: 10 g of raspberry leaf tea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raspberry leaf tea
Description: 10 g of raspberry leaf tea
Study: NCT05773170

Intervention type: DRUG
Intervention: Refralon
Description: 1 mg/ml concentrate for solution for intravenous injection. (Prior to the administration, 2 mL of Refralon® must be diluted to 20 mL in 0.9 % sodium chloride).
Study: NCT05825352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carmellose eye drops
Description: Ocular drops based upon carmellose
Study: NCT04989283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT05007275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1x10^9 vp AZD1222
Description: A single dose of 1x 10\^9 vp AZD1222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5x10^9 vp AZD1222
Description: A single dose of 5x 10\^9 vp AZD1222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1x10^10 vp AZD1222
Description: A single dose of 1x10\^10 vp AZD1222
Study: NCT05346666

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
Description: Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
Description: Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
Study: NCT06024642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V117957
Description: V117957 1 mg - 1 tablet taken orally at bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match V117957 tablets - 1 tablet taken orally at bedtime.
Study: NCT05304351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Antigen High Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Antigen Low Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Adjuvant High Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Adjuvant Middle Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRV-101 Vaccine Adjuvant Low Dose
Description: Suspension for injection administered intramuscularly (IM) in the deltoid region of the non-dominant arm in Month 0 and Month 2 per study schedule
Study: NCT06536660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnesium bone plate and screw fixation in jaw surgery
Description: Participants will undergo jaw surgery based on their clinical indications. High-purity magnesium bone plates and screws will be used for internal fixation during the surgical procedure.